SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences today announced Regina Benjamin, MD, MBA, has joined the Company’s Board of Advisors, effective March 25, 2021. Dr. Benjamin joins the InterVenn Board of Advisors with extensive experience in prevention and population health.
Dr. Benjamin is founder and CEO of BayouClinic/Gulf States Health Policy Center in Bayou La Batre, Alabama, and holds the NOLA.com endowed chair of public health sciences at Xavier University of Louisiana. Dr. Benjamin served as the 18th U.S. Surgeon General from 2009 to 2013 and led the command of the U.S. Public Health Service Commissioned Corps. She was also chair of the National Prevention Council, composed of 17 cabinet-level heads of federal agencies that released the first-ever National Prevention Strategy, whose goal was to change our healthcare system from one based on sickness and disease, to one of wellness and prevention.
Dr. Benjamin serves on various boards including Kaiser Foundation Hospitals and Health Plan, Ascension Health Alliance, and 3 publicly traded healthcare companies. Dr. Benjamin is one of the nation’s leading voices on population and preventive health issues.
“As a clinician who continues to work in the community, taking care of patients helps me stay grounded and connected with the many challenges and struggles they face,” said Dr. Benjamin. “I am pleased to join the InterVenn team as we utilize various disciplines to equally and unequivocally improve patient care. I look forward to contributing to InterVenn’s vision that nobody should be blindsided by disease.”
“We are humbled and tremendously grateful to welcome Regina to our board,” said Aldo Carrascoso, Co-Founder and Chief Executive Officer of InterVenn Biosciences. “Regina’s leadership and experience in a broad spectrum of public health and healthcare management will greatly benefit InterVenn’s strategic planning and cultural growth.”
About InterVenn Biosciences
InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.
Contacts
Andrea Vuturo, press@venn.bio, (888) 706-1670